H ypertension and being overweight or obese have previously been identified as risk factors for diabetes mellitus and frequently coexist.
adverse metabolic effects is present in those with and without abdominal obesity. 6 Identification of risk factors for diabetes mellitus has been a focus for decades, with the ultimate goal of developing strategies to delay or prevent onset of diabetes mellitus in those at highest risk. Based on data from observational and randomized clinical trials, clinical characteristics known to increase risk for drug-induced diabetes mellitus include age, ethnicity, race, body mass index, hypertension, and stroke, among many others. 9 Metabolomics, a rapidly growing field that enables mapping of global biochemical changes associated with disease or treatment, 10 has been used successfully to map pathways implicated in mechanisms of variation of response to drugs. 11 Recently, metabolomics data from an observational study of the Framingham Offspring cohort identified a small cluster of essential amino acids (AAs), including baseline levels of 3 branched-chain amino acids (BCAA), isoleucine (IIe), leucine (Leu), and valine (Val), and 2 aromatic amino acids (AAA), phenylalanine (Phe) and tyrosine (Tyr), as metabolomic risk factors associated with a significant and independent increased risk for diabetes mellitus. 12 This same 5 AA cluster has also been identified as a predictor of IR in young adults. 13 Although the clinical characteristics that predict risk for drug-induced diabetes mellitus are similar to those that predict diabetes mellitus of other pathogeneses, 14, 15 currently no data available assess whether the same profile of BCAA and AAA that predicted diabetes mellitus and IR risk might also predict risk for drug-induced alterations in glucose status. Likewise, although BCAA transaminase 1, BCAT1, and phenylalanine hydroxylase, PAH, genes that catabolize BCAA and AA, respectively, have been previously associated with diabetes mellitus 16 and IR, 17 there are no data regarding the associations of single-nucleotide polymorphisms (SNPs) in these genes with drug-induced metabolic changes. Therefore, in a nested cohort from the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study, we used a targeted pharmacometabolomics-informed pharmacogenomics approach 18 to investigate whether baseline levels of the previously identified BCAA and AAA and SNPs in genes in their catabolic pathways increase the odds of developing IFG, a phenotype associated with significant increased risk of diabetes mellitus and cardiovascular disease after short-term exposure to atenolol.
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Methods
PEAR is a prospective, randomized, parallel group, titration study undertaken to evaluate the pharmacogenomic determinants of the antihypertensive and adverse metabolic responses to atenolol and hydrochlorothiazide in participants with hypertension without a history of heart disease or diabetes mellitus. Details on study design and enrollment criteria have been previously published. 20 The study is registered at clinicaltrials.gov, NCT00246519, http://clinicaltrials.gov/ct2/ show/NCT00246519.
Study Population
PEAR participants were enrolled from primary care clinics at the University of Florida (Gainesville, FL), Emory University (Atlanta, GA), and the Mayo Clinic (Rochester, MN). Because we are seeking to extend findings generated in a primarily white population, this analysis includes a subset of European American men and women with mild-to-moderate essential hypertension, between the ages of 17 and 65, selected for metabolomics profiling and with available genotype information within the atenolol arm of PEAR ( Figure I in the Data Supplement). For metabolomics profiling, patients were divided into quartiles based on the diastolic BP response to atenolol monotherapy. Equal numbers of patients were selected randomly within each response quartile using the PROC SURVEYSELECT procedure (simple random sampling without replacement). Before baseline measurements, those receiving treatment for hypertension at enrollment had all antihypertensive drugs discontinued for a median 27 (interquartile range [IQR] 19-34) days. Participants with IFG (glucose≥100 mg/dL) at baseline were excluded from this analysis.
PEAR Protocol
Written informed consent was obtained voluntarily from all participants, and institutional review board approval was obtained from all study sites, which included University of Florida, the Mayo Clinic, and Emory University. Atenolol was initiated at 50 mg and titrated to 100 mg based on BP>120/70 mm Hg and tolerability. After ≥6 weeks on the final dose, response was determined, including BP measurements and laboratory-based assessments, and results described in this analysis come from this response assessment time point. PEAR is registered at ClinicalTrials.gov, #NCT00246519.
Laboratory Measurements
At baseline and after completion of atenolol monotherapy, fasting blood samples were collected for glucose and insulin. Insulin sensitivity status was calculated using the homeostatic model assessment-IR (HOMA-IR).
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Biochemical Assays
Glucose was measured in plasma on an Hitachi 911 Chemistry Analyzer (Roche Diagnostics) at the central laboratory at the Mayo Clinic, Rochester, MN, using spectrophotometry by an automated enzymatic assay. Plasma insulin was measured using the Access Ultrasensitive Insulin immunoassay system (Beckman Instruments). All samples were tested in duplicate, and data reported are means of the duplicate samples.
AA Quantification
Plasma samples were transferred from the PEAR laboratory to the metabolomics core laboratory, University of California, Davis, where samples were extracted, derivatized, and analyzed as reported previously in great detail. 22, 23 Briefly, mass spectrometry used a Leco Pegasus IV time of flight mass spectrometer with 280°C transfer line temperature, electron ionization at −70 V, and an ion source temperature of 250°C. Mass spectra were acquired from m/z 85 to 500 at 20 spectra/sec and 1750 V detector voltage. Quantitative data were normalized to the sum intensities of all known metabolites and used for statistical investigation.
Genotyping and Quality Control
To explore a potential functional mechanism underlying our observation that the 5 AA signature was associated with development of IFG after exposure to atenolol, we sought to investigate genes in common catabolic pathways. Because we had a limited population (n=184) with available genetic data and that did not have IFG at baseline, we used a candidate gene approach for this analysis. For the BCAAs, we chose to focus on BCAT1, which encodes the cytosolic form of the enzyme BCAA transaminase. This enzyme catalyzes the reversible transamination of branched-chain α-keto acids to branched-chain L-AA essential for cell growth, and importantly, the aminotransferase step is the first step in the catabolic process for Ile, Leu, and Val. For the AAs, we chose to focus on PAH, which encodes the enzyme phenylalanine hydroxylase. Phenylalanine hydroxylase catalyzes the hydroxylation of the aromatic side-chain of phenylalanine to generate tyrosine and is the rate-limiting enzyme of the metabolic pathway that degrades excess phenylalanine.
Genotypes for SNPs in the BCAT1 and PAH genes were obtained from the Omni1M quad GWAS Beadchip. The Omni1M quad is a GWAS chip that used the Infinium II assay, and genotypes were called using BeadStudio software and GenTrain2 calling algorithm. Procedures for quality Control and principal component (PC) analysis for determination of population substructure are described in detail in the Materials section in the Data Supplement. After QC procedures, minor allele frequency filter of >0.05, and linkage disequilibrium and monogenic SNP pruning, a total of 96 SNPs, 69 SNPs in BCAT1, and 27 SNPs in PAH were analyzed in the genetic association study.
Primary Outcome
We examined the association between baseline plasma metabolite level of Ile, Leu, Val, Tyr, and Phe, as well as SNP genotypes and development of IFG, defined as a new occurrence of fasting glucose≥100 mg/dL, 24 after treatment with atenolol monotherapy. After a 12-hour fast, glucose was measured in all participants at baseline, before initiation of atenolol, and again at the end of atenolol therapy. Mean duration of treatment with atenolol was 9 weeks. Participants with a fasting glucose ≥100 mg/dL at baseline were excluded from this study. Participants with a baseline fasting glucose <100 mg/dL and a fasting glucose ≥100 mg/dL at the end of atenolol treatment were considered to have developed IFG. Participants with a baseline fasting glucose <100 mg/dL and a fasting glucose that remained <100 mg/dL at the end of atenolol treatment were considered to have not developed IFG.
Statistical Analyses
Frequencies and percentages were calculated for categorical baseline characteristics and were compared by using χ 2 tests between those who did and did not develop IFG. Means and SDs or medians and interquartile ranges were calculated for continuous baseline characteristics and were compared using t tests or Wilcoxon rank-sum tests, respectively, between those who did and did not develop IFG. Change and percentage change in fasting glucose, baseline glucose, baseline insulin, and baseline AA levels were log-transformed because of non-normal distribution and compared across case/control groups. We used a regression model to assess the association between baseline AA level with the percentage change in glucose, adjusted for age, sex, body mass index, baseline glucose and insulin, and HOMA-IR in the entire cohort with metabolomics data available (n=150). Whether a participant developed IFG as a binary outcome variable was fitted by multiple logistic regression models. In separate analyses, each baseline plasma AA level was entered in the logistic model individually as a primary risk predictor. Because the distribution of those who did and did not develop IFG was significantly different by sex and previous research has shown that plasma AA levels differ significantly by sex, 25 we performed a subgroup analysis where each baseline plasma AA level as a primary risk predictor of IFG development was tested separately by sex. The values of AA level were standardized (mean=0 and SD=1) so that the regression coefficients are interpreted as odds ratio (OR) per SD. 12 ORs for AA level predicting IFG were estimated. For logistic regression analyses, we tested 4 separate models, (1) unadjusted; (2) adjusted for baseline age, sex, and body mass index; (3) model 2 plus fasting glucose and fasting insulin; and (4) model 3 plus HOMA-IR, to test the effect of IR. We evaluated the composite effect of the AAs by combining the individual P values from the model that included HOMA-IR. Because the BCAA and AAA were all strongly correlated (r=0.56-0.91, P<0.0001 for all comparisons), an extension to Fisher combination for correlated tests was performed for testing significance of the composite P value. 26 For AA analyses, P values <0.05 were considered statistically significant.
For pharmacogenomics analyses, deviations from Hardy Weinberg Equilibrium (HWE) were assessed using Fisher Exact Test with α=0.05. The associations of the BCAT1 and PAH SNPs and IFG were evaluated using logistic regression, adjusting for age, sex, baseline glucose, insulin, and HOMA (model 4 above), and the first 2 PCs for ancestry. To account for multiple comparisons, α levels for the SNP associations were set based on the total number of SNPs included in the analysis, which was 96: 0.05/96=0.0005. SNP genotype QC and genetic association analyses were performed in PLINK. 27 All other analyses were performed by using SAS v9.3 (SAS Institute, Cary, NC).
Results
Pharmacometabolomic Analyses
Among the 234 participants randomized to the atenolol group in the PEAR study, metabolomic profiling was performed on 150 ( Figure I in the Data Supplement). Of those participants, 122 did not have IFG at baseline and are the focus of the metabolomics analysis. A total of 24 participants developed IFG during an average 9 weeks of treatment with atenolol. Baseline characteristics of the participants included in the metabolomic analysis are summarized in Table 1 and do not differ from the entire atenolol cohort (data not shown). Although those who developed IFG were more likely to be men, the cohort was similar in age, body mass index, and systolic and diastolic BP in those who did and did not develop IFG. Baseline fasting glucose was higher (Table 1) , and change in glucose after treatment with atenolol was significantly greater among those who developed IFG than those who did not (mean 13.5 mg/dL versus 2.1 mg/dL, P<0.0001; Figure IIA in the Data Supplement). Median baseline plasma levels of Ile, Leu, Val, and Phe were significantly higher in those who developed IFG than those who did not, whereas there was no difference in baseline levels of Tyr ( Figure IIB in the Data Supplement).
Baseline levels of all 5 AAs were significantly associated with percentage change in glucose, even after adjustment for age, sex, body mass index, baseline glucose, and insulin and HOMA-IR. The beta coefficients of the baseline 5 AAs are shown in Table 2 .
Association of Amino Acids With Impaired Fasting Glucose
Association between baseline AA level (per SD increment) and odds for development of IFG for models 1 to 4 in the overall cohort is summarized in Table 1 Figure 1 ). When the P values from the individual AAs were combined, the composite P value was 2×10 −5 for Model 4, indicating a strong association between this 5 AA metabolite profile and odds for IFG after atenolol treatment. In subgroup analysis of odds for IFG according to sex, with the covariates from Model 4, in women (n=6 developed IFG and n=62 did not develop IFG), the ORs ranged from 1.18 to 3.67; however, none of the associations reaches statistical significance likely because of the small number of women who developed IFG. In men (n=18 developed IFG and n=36 did not develop IFG), the ORs ranged from 1.75 to 2.47, and baseline levels of Ile, Tyr, and Phe were associated with significantly increased adjusted odds for developing IFG. Data summarizing adjusted odds for IFG according to sex are presented in Table II in the Data Supplement.
Pharmacogenetic Analysis
Patients with the PAH rs2245360 AA genotype had the highest incidence of IFG (41.7%) compared with patients with AG genotype (15.2%) and GG genotype (7.4%), P for trend=0.0003, which achieved statistical significance (Figure 2) . In analyses of odds per allele for developing IFG after atenolol monotherapy, PAH rs2245360 had adjusted ORs of 3.51, 95% confidence interval 1.62 to 7.63, P=0.0015. None of the BCAT1 SNPs tested achieved Bonferroni-corrected statistical significance for development of IFG.
Discussion
We have shown, for the first time, that baseline plasma levels of Ile, Leu, Val, Tyr, and Phe, as well as a gene in a catabolic pathway, are strongly associated with increased odds of developing IFG in participants with hypertension, treated relatively short term (9 weeks) with atenolol, a commonly prescribed β-blocker. Importantly, IFG is an independent predictor of diabetes mellitus, 4 and adding measures of anthropometrics and IR status into prediction models are often more informative for assessing diabetes mellitus risk. 28 Here, we show that baseline levels of 4 of the 5 AAs investigated are significantly different in those who do and do not develop IFG, and that the AAs can further inform a prediction model for drug-induced IFG, an early metabolic risk phenotype in the diabetes mellitus continuum. Our data extend recent findings from the Framingham Offspring study, 12 an observational study primarily in whites, which showed a strong association between these AAs and incident diabetes mellitus.
Overweight, obesity, glucose intolerance, and IR have been closely linked through many important biochemical and regulatory pathways. 29 Knowledge that higher blood concentrations of Ile, Leu, Val, Tyr, and Phe are elevated in people with obesity, IR, or diabetes mellitus is not new. 30 The continued rise in prevalence of risk conditions for diabetes mellitus in the last 2 decades has increased the need to better understand all relevant underlying pathways. Recent developments in metabolite profiling or metabolomics have provided insight into additional biochemical pathways that play an important role in glucose and insulin regulation. 31 In a study comparing lean and obese individuals, BCAA and AAA were recently recognized as a metabolite cluster strongly associated with insulin sensitivity. 32 Additionally, BCAA have been associated with coronary artery disease 33 and diabetes mellitus. 12 We have further confirmed BCAA as a significant predictor for atenolol-induced IFG in a population of middle-aged, otherwise healthy individuals with hypertension, providing additional evidence for its use as an important risk biomarker. In an analysis stratified by sex, Huffman et al showed that a cluster of large neutral AAs (Leu/Ile ratio, Val, Phe, Try, proline, and histidine) along with uric acid was a significant independent predictor of insulin sensitivity in both men and women. 25 In our subgroup analysis evaluating the 5 AA signature stratified by sex, we confirmed an association with increased odds for IFG in men and saw similar, although nonsignificant, trends in women. Our inability to confirm an association in women is likely because of the small number of women who developed IFG in our study, and this warrants further investigation in a larger cohort of women treated with atenolol.
Importantly, evidence also suggests that these AAs may play a causal role in metabolic dysregulation. A study evaluating the effect of a high-fat diet with or without BCAA supplementation in rats demonstrated that the high-fat plus BCAA diet resulted in a higher rate of IR than the high-fat diet alone. 32 Similarly, a small study of healthy men who were infused a solution containing 18 AAs showed that AAs impair both insulin-mediated suppression of glucose production and insulin-stimulated glucose disposal in skeletal muscle. 34 Together, these data suggest that these metabolites contribute to the development of metabolic dysregulation and are not just innocent bystanders in the metabolic disease continuum. 35 Our data from a relatively overweight/obese hypertensive population suggest that treatment with atenolol may be another environmental exposure that has interactions among BCAA, AAA, and glucose regulation, as we observed significantly increased odds for IFG, an important early predictor for diabetes mellitus, associated with all AA tested.
PAH, on chromosome 12 (12q22-q24.2), has been associated with altered metabolic status. In the black cohort from the Insulin Resistance Atherosclerosis Family Study, strong linkage between the 12q22-24.2 region (PAH) and acute insulin response to glucose was observed. 17 Linkage to fasting insulin has previously been reported near 12q23 in the Amish as well. 36 Our observation of a significant difference in the development of IFG according to PAH rs2245360 genotype suggests this gene may play an important functional role in metabolic risk.
β-adrenergic blockers have long been recommended as firstline therapy for the treatment of hypertension, especially in patients with coronary artery disease. 37 However, β-blockers have been implicated in altering glucose homeostasis, primarily through the inhibition of pancreatic insulin secretion and promoting IR. β-receptor selectivity seems to play a role in the degree of downstream metabolic effects, which include not only glucose increases but also weight gain and dyslipidemia. Nonselective and higher dose selective agents result in the largest adverse metabolic changes. 38 Newer β-blockers including nebivolol and carvedilol seem to minimally affect glucose homeostasis and improve insulin sensitivity. 39, 40 Although the mechanisms underlying this differential effect on glucose remain unclear, they likely extend beyond β-blockade. Atenolol, the β-blocker used to treat participants in PEAR, is cardioselective, and the 100 mg dose used is the dose typically used to treat hypertension. We observe that AAs and PAH, a gene previously associated with insulin sensitivity, are also associated with atenolol-associated IFG. These data suggest the underlying mechanisms of drug-induced and primary dysmetabolism may be the same. Drugs may be an environmental trigger in patients with metabolic risk factors.
There are a few limitations of our study that are worthy of mention. First, although we targeted our analysis on a metabolite cluster previously identified for risk of diabetes mellitus in a population of whites, we performed our analyses only in a cohort of European Americans. Because our cohort is relatively small, particularly for analyses by sex, these results should be replicated in other populations with hypertension, untreated and treated with β-blockers and other drugs that possess adverse metabolic risks, for confirmation. Second, although we did observe a significant association with IFG in our cohort treated with atenolol, we cannot exclude that other metabolites are also playing a role. Third, our findings were identified among European American individuals with hypertension treated with atenolol and as such are only generalizable among similar patient populations. However, use of β-blockers in general, and atenolol specifically, is highly prevalent. In 2010, >36 million prescriptions were filled for atenolol or atenolol combinations in the United States. 41 Finally, further investigation is warranted to (1) determine whether this 5-AA signature is causal in the development of IFG or is simply a marker of IR and impaired beta cell function, and (2) confirm our pharmacogenetic association and extend this finding to other antihypertensive agents associated with hyperglycemia, including thiazide diuretics and other race and ethnic groups at high risk for metabolic dysfunction.
In conclusion, we have extended the previous findings associating BCAA and AAAs with incident diabetes mellitus to atenolol-induced IFG development. Our findings are important as they suggest novel biomarkers for the identification of those individuals at risk of developing antihypertensive treatment-induced diabetes mellitus. They may also provide insights to help better understand the mechanisms of β-blocker-induced dysglycemia. Although pharmacogenomics has shown to be informative with regard to drug-gene interactions for β-blocker BP response, 42 this study represents one of the first to use a targeted pharmacometabolomic investigation combined with a pharmacogenomics investigation informed by the pharmacometabolomic findings for the antihypertensive drug-induced dysglycemia phenotype. With the prevalence of overweight, obesity, IR, hypertension, and diabetes mellitus on the rise not only in the United States but worldwide, understanding as many aspects of the mechanistic underpinnings of drug-induced adverse metabolic effects as possible is important. Pharmacometabolomics is a new but rapidly growing field that has promise in defining pathways implicated in mechanisms of variation of response to therapies and complements information gained from a pharmacogenomics approach. Together, they may be of immense value as the focus for drug therapy moves toward a personalized approach.
